Use of tetracycline as an inhibitor of matrix metalloproteinase activity secreted by human bone-metastasizing cancer cells

Invasion and Metastasis

Volumn 17, Issue 6, 1997, Pages 312-322

  Duivenvoorden, Wilhelmina C M ^a   Hirte, Holger W ^a   Singh, Gurmit ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b JURAVINSKI CANCER CENTRE   (Canada)

Author keywords

Bone; Matrix metalloproteinases; Metastasis; Tetracycline

Indexed keywords

CHELATING AGENT; DOXYCYCLINE; ENZYME INHIBITOR; GELATINASE A; MATRIX METALLOPROTEINASE; MINOCYCLINE; TETRACYCLINE; ZINC ION;

ANIMAL CELL; ARTICLE; BONE MATRIX; BONE METASTASIS; BREAST CANCER; CANCER CELL; CANCER MORTALITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONCENTRATION; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; MORBIDITY; MOUSE; NONHUMAN; PROSTATE CANCER; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; ANTI-BACTERIAL AGENTS; BLOTTING, WESTERN; BONE NEOPLASMS; BREAST NEOPLASMS; CELL SURVIVAL; COLLAGENASES; CULTURE MEDIA, CONDITIONED; DOXYCYCLINE; EXTRACELLULAR MATRIX; GELATINASES; HUMANS; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MELANOMA; METALLOENDOPEPTIDASES; MICE; MINOCYCLINE; PROSTATIC NEOPLASMS; PROTEASE INHIBITORS; TETRACYCLINE; TETRACYCLINES; TUMOR CELLS, CULTURED;

EID: 0031545846     PISSN: 02511789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Kanis JA: Bone and cancer: Pathophysiology and treatment of metastases. Bone 1995;17:101S-105S.
2. Furcht LT, Skubitz APN, Fields GB: Tumor cell invasion, matrix metalloproteinases, and the dogma. Lab Invest 1994;70:781-783.
3. Pauli BU, Knudson W: Tumor invasion: A consequence of destructive and compositional matrix alterations. Hum Pathol 1988;19:628-639.
4. Sanchez-Sweatman OH, Singh G, Krüger A, Khokha R, Duivenvoorden WCM, Orr FW: Human skeletal metastatic cell lines directly degrade bone matrix using matrix metalloproteinases. Br J Cancer, in press.
5. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980; 284:67-68.
6. Tarin D, Hoyt BJ, Evans DJ: Correlation of collagenase secretion with metastatic-colonization potential in naturally occurring murine mammary tumors. Br J Cancer 1982;46: 266-278.
7. Turpeeniemi-Hujanen T, Thorgeirsson UP, Hart IR, Grant SS, Liotta LA: Expression of collagenase IV (basement membrane collagenase) activity in murine tumor cell hybrids that differ in metastatic potential. J Natl Cancer Inst 1985;75:99-103.
8. Nakaijama M, Welch DR, Belloni PN, Nicolson GL: Degradation of basement membrane type IV collagen and lung subendothelial matrix by rat mammary adenocarcinoma cell clones of differing metastatic potentials. Cancer Res 1987;47:4869-4876.
9. Sreenath T, Matrisian LM, Stetler-Stevenson W, Gattoni-Celli S, Pozzatti RO: Expression of matrix metalloproteinase genes in transformed rat cell lines of high and low metastatic potential. Cancer Res 1992; 52:4942-4947.
10. Stearns ME, Wang M: Immunoassays of the metalloproteinase (MMP-2) and tissue inhibitor of metalloproteinase (TIMP-1 and -2) levels in noninvasive and metastatic PC-3 clones: Effects of taxol. Oncol Res 1994;6:195-201.
11. Stearns ME, Wang M: Taxol blocks processes essential for prostate tumor cell (PC-3 ML) invasion and metastases. Cancer Res 1992;52: 3776-3781.
12. Schultz RM, Silberman S, Persky B, Bajkowski AS, Carmichael DF: Inhibition of human recombinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonization by murine B16-F10 melanoma cells. Cancer Res 1988; 48:5539-5545.
13. Alvarez OA, Carmichael DF, DeClerck YA: Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases. J Natl Cancer Inst 1990;82: 589-595.
14. Khokha R: Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1. J Natl Cancer Inst 1994;86: 299-304.
15. DeClerck YA, Perez N, Shimada H, Boone TC, Langley KE, Taylor SM: Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res 1992;52:701-708.
16. Yoneda T, Sasaki A, Dunstan C, Williams PJ, Bauss F, DeClerck YA, Mundy GR: Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bis-phosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest 1997;99: 2509-2517.
17. Hua J, Muschel RJ: Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res 1996;56:5279-5284.
18. Wang X, Fu X, Brown PD, Crimmin MJ, Hoffman RM: Matrix metalloproteinase inhibitor BB-94 (Batimastat) inhibits human colon tumor growth and spread in a patient-like orthotropic model in nude mice. Cancer Res 1994;54:4726-4728.
19. Greenwald RA, Golub LM, Lavietes B, Ramamurthy NS, Gruber B, Laskin RS, McNamara TF: Tetracy-clines inhibit human synovial collagenase in vivo and in vitro. J Rheumatol 1987;14:28-32.
20. Burns FR, Stack MS, Gray RG, Paterson CA: Inhibition of purified collagenase from alkali-burned rabbit corneas. Invest Ophthalmol Vis Sci 1989;30:1569-1575.
21. Golub LM, Ramamurthy NS, McNamara TF, Greenwald RA, Rifkin BR: Tetracyclines inhibit connective tissue breakdown: New therapeutic implications for an old family of drugs. Crit Rev Oral Biol Med 1991;2:297-322.
22. Paemen L, Martens P, Norga K, Masure S, Roets E, Hoogmartens J, Opdenakker G: The gelatinase inhibitory activity of tetracyclines and chemically modified tetracycline analogues as measured by a novel microtiter assay for inhibitors. Biochem Pharmacol 1996;52:105-111.
23. Hartman A, Wess D, Witte I: Enhanced cyto-and genotoxicity of tetracycline in Wilson disease fibroblasts. Mutat Res 1995;348:7-12.
24. van den Bogert C, Dontje BH, Melis TE, Romijn JC, van Dongen JW, Kroon AM: Arrest of proliferation of renal and prostate carcinomas of human origin by inhibition of mitochondrial protein synthesis. Cancer Res 1986;46:3283-3289.
25. Green J: The physiochemical structure of bone: Cellular and noncellular elements. Miner Electrolyte Metab 1994;20:7-15.
26. Cailleau R, Young R, Olive M, Reeves WJ Jr: Breast tumor cell lines from pleural effusions. J Natl Cancer Inst 1974;53:661-674.
27. Fidler IJ, Gersten DM, Hart IR: The biology of cancer invasion and metastasis. Adv Cancer Res 1978;28: 149-250.
28. Mbalaviele G, Dunstan CR, Sasaki A, Williams PJ, Mundy GR, Yoneda T: E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model. Cancer Res 1996;56: 4063-4070.
29. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW: Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979;17:16-23.
30. Shervrin DH, Kukreja SC, Ghosh L, Lad TE: Development of skeletal metastasis by human prostate cancer in athymic nude mice. Clin Exp Metastasis 1988;6:401-409.
31. Smith HS: In vitro properties of epithelial cell lines established from human carcinomas and nonmalignant tissue. J Natl Cancer Inst 1979;62: 225-230.
32. Owens RB, Smith HS, Nelson-Rees WA, Springer EL: Epithelial cell cultures from normal and cancerous human tissues. J Natl Cancer Inst 1976;56:843-849.
33. Heussen C, Dowdle EB: Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and co-polymerized substrates. Anal Biochem 1980;102:196-202.
34. Kroon AM, Dontje BHJ, Holtrop M, van den Bogert C: The mitochondrial genetic system as a target for chemotherapy: Tetracyclines as cytostatics. Cancer Lett 1984;25: 33-40.
35. Yu M, Sato H, Seiki M, Thompson EW: Complex regulation of membrane type matrix metalloproteinase expression and matrix metalloproteinase-2 activation by concanavalin A in MDA-MB-231 human breast cancer cells. Cancer Res 1995;55:3272-3277.
36. Azzam HS, Arand G, Lippman ME, Thompson EW: Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of MMP-2 production. J Natl Cancer Inst 1993;85:1758-1764.
37. Mackay AR, Ballin M, Pelina MD, Farina AR, Nason AM, Hartzler JL, Thorgeirsson UP: Effect of phorbol ester and cytokines on matrix metalloproteinase and tissue inhibitor of metalloproteinase expression in tumor and normal cell lines. Invasion Metastasis 1992;12:168-184.
38. Aimes RT, Quigley JP: Matrix metalloproteinase-2 is an interstitial collagenase. J Biol Chem 1995;270: 5872-5876.
39. Woessner JF Jr: The family of matrix metalloproteinases. Ann NY Acad Sci 1994;732:11-21.
40. Nagase H, Ogata Y, Suzuki K, Enghild JJ, Salvesen G: Substrate specificities and activation mechanisms of matrix metalloproteinases. Biochem Soc Trans 1991;19:715-718.
41. Okada Y, Naka K, Kawamura K, Matsumoto T, Nakanishi I, Fujimoto N, Sato H, Seiki M: Localization of matrix metalloproteinase 9 (92-kilodalton gelatinase/type IV collagenase = gelatinase B) in osteoclasts: Implications for bone resorption. Lab Invest 1995;72:311-322.
42. Meikle MC, Bord S, Hembry RM, Reynolds JJ: The synthesis of collagenase, gelatinase-A (72 kDa) and -B (95 kDa), and TIMP-1 and -2 by human osteoblasts from normal and arthritic bone. Bone 1995;17:255-260.
43. Sorsa T, Ding Y, Salo T, Lauhio A, Teronen O, Ingman T, Ohtani H, Andoh N, Takena S, Konttinen YT: Effects of tetracyclines on neutrophil, gingival, and salivary collagenases. Ann NY Acad Sci 1994;732: 112-131.
44. Manicourt DH, Lefevbre V: An assay for matrix metalloproteinases and other proteases acting on proteoglycans, casein, or gelatin. Anal Biochem 1993;215:171-179.
45. Williams S, Wakisaka A, Zeng QQ, Barnes J, Martin G, Wechter WJ, Liang CT: Minocycline prevents the decrease in bone mineral density and trabecular bone in ovariectomized aged rats. Bone 1996;19:637-644.
46. Sasaki T, Ramamurthy NS, Golub LM: Tetracycline administration increases collagen synthesis in osteoblasts of streptozotocin-induced diabetic rats: A quantitative autoradiography study. Calcif Tissue Int 1992;50:411-419.
47. Body JJ, Coleman RE, Piccart M: Use of bisphosphonates in cancer patients. Cancer Treat Rev 1996;22: 265-287.
48. Taraboletti G, Garofalo A, Belotti D, Drudis T, Borsotti P, Scanziani E, Brown P, Giavazzi R: Inhibition of angiogenesis and murine hemangioma growth by Batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst 1995;87:293-298.